Aura Biosciences, Inc. (AURA) stock
AURANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.15−0.07 (-0.97%)
Close on Nov 17, 2026Market cap $741.49MP/E –Yield –
Aura Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Aura Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$103.01M. For fiscal 2025 it was -$84.74M. The highest annual figure on record is -$24.32M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$84.74M | – |
| FY2024 | Dec 31, 2024 | -$79.81M | – |
| FY2023 | Dec 31, 2023 | -$63.85M | – |
| FY2022 | Dec 31, 2022 | -$54.60M | – |
| FY2021 | Dec 31, 2021 | -$32.41M | – |
| FY2020 | Dec 31, 2020 | -$24.32M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$32.50M | – |
| Q1 FY2026 | Mar 31, 2026 | -$29.89M | – |
| Q4 FY2025 | Dec 31, 2025 | -$20.47M | – |
| Q3 FY2025 | Sep 30, 2025 | -$20.14M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.77M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.36M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.95M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.27M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.13M | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.45M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.39M | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.40M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.65M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.41M | – |
| Q4 FY2022 | Dec 31, 2022 | -$18.01M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.76M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.63M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.20M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.09M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.69M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.50M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.14M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.76M | – |
See a number that looks wrong?